RE:RE:USA Inflation Reduction Act (IRA) 2022 Re: Biotech and ChinaMarch 08, 2024 - Yesterday's "State of the Union Address" further emphasized that orphan/rare drugs would be exempt from future price negotiations while the White House is looking to increase the Inflation Reduction Act’s (IRA) current negotiation cap of 20 drugs per year to 50 drugs annually, focusing on medications crucial for seniors such as heart disease, cancer and diabetes medicines.
Since ONCY's pelareorep is a "platform drug" that can be approved for multiple cancer indications involving multiple combinations with different drugs, pelareorep will be able to experience exemptions from pricing negotiations in all the indications that pelareorep will be approved in, notwithstanding that the IRA exemption applies only to orphan drugs with a single approved indication.
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2808362
https://www.biospace.com/article/biden-calls-for-expanding-ira-s-drug-price-negotiation-program/